|
1
|
Newell EW and Cheng Y: Mass cytometry:
Blessed with the curse of dimensionality. Nat Immunol. 17:890–895.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spitzer MH and Nolan GP: Mass cytometry:
Single cells, many features. Cell. 165:780–791. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Z, Gerstein M and Snyder M: RNA-Seq:
A revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stegle O, Teichmann SA and Marioni JC:
Computational and analytical challenges in single-cell
transcriptomics. Nat Rev Genet. 16:133–145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bendall SC, Simonds EF, Qiu P, Amir el-AD,
Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI,
et al: Single-cell mass cytometry of differential immune and drug
responses across a human hematopoietic continuum. Science.
332:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bodenmiller B, Zunder ER, Finck R, Chen
TJ, Savig ES, Bruggner RV, Simonds EF, Bendall SC, Sachs K, Krutzik
PO and Nolan GP: Multiplexed mass cytometry profiling of cellular
states perturbed by small-molecule regulators. Nat Biotechnol.
30:858–867. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bendall SC, Davis KL, Amir el-AD, Tadmor
MD, Simonds EF, Chen TJ, Shenfeld DK, Nolan GP and Pe'er D:
Single-cell trajectory detection uncovers progression and
regulatory coordination in human B cell development. Cell.
157:714–725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Good Z, Sarno J, Jager A, Samusik N,
Aghaeepour N, Simonds EF, White L, Lacayo NJ, Fantl WJ, Fazio G, et
al: Single-cell developmental classification of B cell precursor
acute lymphoblastic leukemia at diagnosis reveals predictors of
relapse. Nat Med. 24:474–483. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Behbehani GK, Bendall SC, Clutter MR,
Fantl WJ and Nolan GP: Single-cell mass cytometry adapted to
measurements of the cell cycle. Cytometry A. 81:552–566. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Knapp DJ, Hammond CA, Aghaeepour N, Miller
PH, Pellacani D, Beer PA, Sachs K, Qiao W, Wang W, Humphries RK, et
al: Distinct signaling programs control human hematopoietic stem
cell survival and proliferation. Blood. 129:307–318. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Porpiglia E, Samusik N, Ho ATV, Cosgrove
BD, Mai T, Davis KL, Jager A, Nolan GP, Bendall SC, Fantl WJ and
Blau HM: High-resolution myogenic lineage mapping by single-cell
mass cytometry. NaT Cell Biol. 19:558–567. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiu P, Simonds EF, Bendall SC, Gibbs KD
Jr, Bruggner RV, Linderman MD, Sachs K, Nolan GP and Plevritis SK:
Extracting a cellular hierarchy from high-dimensional cytometry
data with SPADE. Nat Biotechnol. 29:886–891. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amir el-AD, Davis KL, Tadmor MD, Simonds
EF, Levine JH, Bendall SC, Shenfeld DK, Krishnaswamy S, Nolan GP
and Pe'er D: viSNE enables visualization of high dimensional
single-cell data and reveals phenotypic heterogeneity of leukemia.
Nat Biotechnol. 31:545–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lavin Y, Kobayashi S, Leader A, Amir ED,
Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH,
et al: Innate immune landscape in early lung adenocarcinoma by
paired single-cell analyses. Cell. 169:750–765.e17. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Minn AJ and Wherry EJ: combination cancer
therapies with immune checkpoint blockade: Convergence on
interferon signaling. Cell. 165:272–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
June CH, O'Connor RS, Kawalekar OU,
Ghassemi S and Milone MC: CAR T cell immunotherapy for human
cancer. Science. 359:1361–1365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Syn NL, Teng MWL, Mok TSK and Soo RA:
De-novo and acquired resistance to immune checkpoint targeting.
Lancet Oncol. 18:e731–e741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dougall WC, Roman Aguilera A and Smyth MJ:
Dual targeting of RANKL and PD-1 with a bispecific antibody
improves anti-tumor immunity. Clin Transl Immunol. 8:e010812019.
View Article : Google Scholar
|
|
19
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oliver AJ, Davey AS, Keam SP, Mardiana S,
Chan JD, von Scheidt B, Beavis PA, House IG, Van Audernaerde JR,
Darcy PK, et al: Tissue-specific tumor microenvironments influence
responses to immunotherapies. Clin Transl Immunol. 8:e10942019.
View Article : Google Scholar
|
|
21
|
Pitt JM, Vétizou M, Daillère R, Roberti
MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M,
Kroemer G and Zitvogel L: Resistance mechanisms to
immune-checkpoint blockade in cancer: Tumor-intrinsic and
-extrinsic factors. Immunity. 44:1255–1269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilson RAM, Evans TRJ, Fraser AR and Nibbs
RJB: Immune checkpoint inhibitors: New strategies to checkmate
cancer. Clin Exp Immunol. 191:133–148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marhelava K, Pilch Z, Bajor M,
Graczyk-Jarzynka A and Zagozdzon R: Targeting negative and positive
immune checkpoints with monoclonal antibodies in therapy of cancer.
Cancers. 11:17562019. View Article : Google Scholar
|
|
24
|
Bhandaru M and Rotte A: monoclonal
antibodies for the treatment of melanoma: Present and future
strategies. Methods Mol Biol. 1904:83–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang C, Cao S, Li N, Jiang L and Sun T:
PD-1 and PD-L1 correlated gene expression profiles and their
association with clinical outcomes of breast cancer. Cancer Cell
Int. 19:2332019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Guo G, Guan H, Yu Y, Lu J and Yu
J: Challenges and potential of PD-1/PD-L1 checkpoint blockade
immunotherapy for glioblastoma. J Exp Clin Cancer Res. 38:872019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gettinger S, Choi J, Hastings K, Truini A,
Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al:
Impaired HLA class I antigen processing and presentation as a
mechanism of acquired resistance to immune checkpoint inhibitors in
lung cancer. Cancer Discov. 7:1420–1435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chevrier S, Levine JH, Zanotelli VRT,
Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H,
et al: An immune atlas of clear cell renal cell carcinoma. Cell.
169:736–749.e18. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krieg C, Nowicka M, Guglietta S, Schindler
S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP and
Becher B: High-dimensional single-cell analysis predicts response
to anti-PD-1 immunotherapy. Nat Med. 24:144–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heher EC, Goes NB, Spitzer TR, Raje NS,
Humphreys BD, Anderson KC and Richardson PG: Kidney disease
associated with plasma cell dyscrasias. Blood. 116:1397–1404. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suen H, Brown R, Yang S, Ho PJ, Gibson J
and Joshua D: The failure of immune checkpoint blockade in multiple
myeloma with PD-1 inhibitors in a phase 1 study. Leukemia.
29:1621–1622. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rosenblatt J, Glotzbecker B, Mills H,
Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W,
Schickler M, et al: PD-1 blockade by CT-011, anti-PD-1 antibody,
enhances ex vivo T-cell responses to autologous dendritic
cell/myeloma fusion vaccine. J Immunother. 34:409–418. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ray A, Das DS, Song Y, Richardson P,
Munshi NC, Chauhan D and Anderson KC: Targeting PD1-PDL1 immune
checkpoint in plasmacytoid dendritic cell interactions with T
cells, natural killer cells and multiple myeloma cells. Leukemia.
29:1441–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jelinek T, Paiva B and Hajek R: Update on
PD-1/PD-L1 inhibitors in multiple myeloma. Front Immunol.
9:24312018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kotecha N, Krutzik PO and Irish JM:
Web-based analysis and publication of flow cytometry experiments.
Curr Protoc Cytom 10: Unit. 10:2010.
|
|
38
|
Maecker HT, McCoy JP and Nussenblatt R:
Standardizing immunophenotyping for the human immunology project.
Nat Rev Immunol. 12:191–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Hendrix A, Hernot S, Lemaire M, De
Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken
K and Menu E: Bone marrow stromal cell-derived exosomes as
communicators in drug resistance in multiple myeloma cells. Blood.
124:555–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, De Veirman K, Faict S, Frassanito
MA, Ribatti D, Vacca A and Menu E: Multiple myeloma exosomes
establish a favourable bone marrow microenvironment with enhanced
angiogenesis and immunosuppression. J Pathol. 239:162–173. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu J, Hamrouni A, Wolowiec D, Coiteux V,
Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells
from multiple myeloma patients express B7-H1 (PD-L1) and increase
expression after stimulation with IFN-{gamma} and TLR ligands via a
MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 110:296–304.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Latchman Y, Wood CR, Chernova T, Chaudhary
D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al:
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nat Immunol. 2:261–268. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zelle-Rieser C, Thangavadivel S,
Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R and
Jöhrer K: T cells in multiple myeloma display features of
exhaustion and senescence at the tumor site. J Hematol Oncol.
9:1162016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mozaffari F, Hansson L, Kiaii S, Ju X,
Rossmann ED, Rabbani H, Mellstedt H and Osterborg A: Signalling
molecules and cytokine production in T cells of multiple
myeloma-increased abnormalities with advancing stage. Br J
Haematol. 124:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Benson DM Jr, Bakan CE, Mishra A,
Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J,
Smith MK, et al: The PD-1/PD-L1 axis modulates the natural killer
cell versus multiple myeloma effect: A therapeutic target for
CT-011, a novel monoclonal anti-PD-1 antibody. Blood.
116:2286–2294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu
Z, Zhang J, Benson DM, He K, Caligiuri MA and Yu J: The mechanism
of anti-PD-L1 antibody efficacy against PD-L1-negative tumors
identifies NK cells expressing PD-L1 as a cytolytic effector.
Cancer Discov. 9:1422–1437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guo Y, Feng X, Jiang Y, Shi X, Xing X, Liu
X, Li N, Fadeel B and Zheng C: PD1 blockade enhances cytotoxicity
of in vitro expanded natural killer cells towards myeloma cells.
Oncotarget. 7:48360–48374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lesokhin AM, Ansell SM, Armand P, Scott
EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ,
Lebovic D, et al: Nivolumab in patients with relapsed or refractory
hematologic malignancy: Preliminary results of a phase Ib study. J
Clin Oncol. 34:2698–2704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rosenblatt J and Avigan D: Targeting the
PD-1/PD-L1 axis in multiple myeloma: A dream or a reality? Blood.
129:275–279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Esensten JH, Helou YA, Chopra G, Weiss A
and Bluestone JA: CD28 costimulation: From mechanism to therapy.
Immunity. 44:973–988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Akbar AN and Henson SM: Are senescence and
exhaustion intertwined or unrelated processes that compromise
immunity? Nat Rev Immunol. 11:289–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Paiva B, Mateos MV, Sanchez-Abarca LI,
Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT,
Bargay J, de Arriba F, et al: Spanish myeloma group/program study
and treatment of hematological malignancies cooperative study
groups: Immune status of high-risk smoldering multiple myeloma
patients and its therapeutic modulation under LenDex: A
longitudinal analysis. Blood. 127:1151–1162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hui E, Cheung J, Zhu J, Su X, Taylor MJ,
Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I and Vale RD: T
cell costimulatory receptor CD28 is a primary target for
PD-1-mediated inhibition. Science. 355:1428–1433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kamphorst AO, Wieland A, Nasti T, Yang S,
Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et
al: Rescue of exhausted CD8 T cells by PD-1-targeted therapies is
CD28-dependent. Science. 355:1423–1427. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wikenheiser DJ and Stumhofer JS: ICOS
co-stimulation: Friend or foe? Front Immunol. 7:3042016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou DM, Xu YX, Zhang LY, Sun Y, Wang ZY,
Yuan YQ and Fu JX: The role of follicular T helper cells in
patients with malignant lymphoid disease. Hematology. 22:412–418.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Feyler S, Scott GB, Parrish C, Jarmin S,
Evans P, Short M, McKinley K, Selby PJ and Cook G: Tumour cell
generation of inducible regulatory T-cells in multiple myeloma is
contact-dependent and antigen-presenting cell-independent. PLoS
One. 7:e359812012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Scott GB, Carter C, Parrish C, Wood PM and
Cook G: Downregulation of myeloma-induced ICOS-L and regulatory T
cell generation by lenalidomide and dexamethasone therapy. Cell
Immunol. 297:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Görgün G, Samur MK, Cowens KB, Paula S,
Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, et
al: Lenalidomide enhances immune checkpoint blockade-induced immune
response in multiple myeloma. Clin Cancer Res. 21:4607–4618. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Perez-Gracia JL, Labiano S, Rodriguez-Ruiz
ME, Sanmamed MF and Melero I: Orchestrating immune check-point
blockade for cancer immunotherapy in combinations. Curr Opin
Immunol. 27:89–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Goulding J, Tahiliani V and Salek-Ardakani
S: OX40:OX40L axis: Emerging targets for improving poxvirus-based
CD8(+) T-cell vaccines against respiratory viruses. Immunol Rev.
244:149–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chester C, Sanmamed MF, Wang J and Melero
I: Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical
results, and future strategies. Blood. 131:49–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chao MP, Weissman IL and Majeti R: The
CD47-SIRPα pathway in cancer immune evasion and potential
therapeutic implications. Curr Opin Immunol. 24:225–232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu X, Pu Y, Cron K, Deng L, Kline J,
Frazier WA, Xu H, Peng H, Fu YX and Xu MM: CD47 blockade triggers T
cell-mediated destruction of immunogenic tumors. Nat Med.
21:1209–1215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Weiskopf K: Cancer immunotherapy targeting
the CD47/SIRPα axis. Eur J Cancer. 76:100–109. 2017. View Article : Google Scholar : PubMed/NCBI
|
